India CDMO Market by Product Type, Application, and End-Use: Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

Description

Persistence Market Research has recently released a comprehensive report on the India Contract Development and Manufacturing Organization (CDMO) market. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the Indian CDMO market from 2024 to 2031.

Key Insights:

India CDMO Market Size (2024E): US$ 22.1 Bn
Projected Market Value (2031F): US$ 54.7 Bn
Market Growth Rate (CAGR 2024 to 2031): 13.8%

India CDMO Market - Report Scope:

The Indian CDMO market encompasses a wide array of services, including drug development, manufacturing, and packaging for the pharmaceutical and biotechnology sectors. This sector is crucial in accelerating drug pipelines, optimizing production costs, and enhancing scalability for pharmaceutical companies. Key market players cater to small, medium, and large pharmaceutical enterprises, offering tailored solutions for formulation development, clinical trials, and large-scale production.

Market Growth Drivers:

The growth of the Indian CDMO market is propelled by increasing outsourcing activities by pharmaceutical companies to focus on core R&D, reduce operational costs, and enhance time-to-market for new drugs. India's cost-efficient manufacturing capabilities, skilled workforce, and adherence to international regulatory standards further boost its position as a preferred CDMO destination. Additionally, the rising prevalence of chronic diseases, coupled with the growing demand for generic drugs, has amplified the need for efficient drug manufacturing services. Advances in biologics and biosimilars also contribute to the expansion of CDMO services.

Market Restraints:

Despite promising growth prospects, the Indian CDMO market faces challenges such as intense competition from global players, compliance with stringent international regulatory standards, and fluctuating raw material costs. Limited infrastructure in smaller CDMOs and reliance on imports for specialized equipment pose additional hurdles. Addressing these constraints will require substantial investment in infrastructure and capacity building, along with fostering collaborations between industry stakeholders and regulatory bodies.

Market Opportunities:

The Indian CDMO market presents significant growth opportunities driven by advancements in biologics, personalized medicine, and digital manufacturing technologies. The emergence of Artificial Intelligence (AI) and Machine Learning (ML) in drug development processes can enhance efficiency and reduce timelines. Expanding global demand for high-quality yet affordable pharmaceutical products positions Indian CDMOs as strategic partners for multinational corporations. Furthermore, initiatives by the Indian government, such as "Make in India" and incentives for pharmaceutical manufacturing, provide a conducive environment for market growth.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the Indian CDMO market?
How do Indian CDMOs compare globally in terms of cost and quality?
Which therapeutic areas and drug types offer the most growth potential in the Indian CDMO market?
Who are the leading players in the Indian CDMO market, and what strategies are they employing to maintain competitiveness?
What are the emerging trends and future prospects in the Indian CDMO landscape?

Competitive Intelligence and Business Strategy:

Prominent players in the Indian CDMO market, including Piramal Pharma Solutions, Jubilant Life Sciences, and Divi's Laboratories, emphasize innovation, cost efficiency, and regulatory compliance to maintain a competitive edge. These companies invest in expanding manufacturing capabilities, adopting cutting-edge technologies, and establishing strategic partnerships with global pharmaceutical firms. Collaborations with biotech startups and academic institutions also play a vital role in driving innovation and market expansion.

Key Companies Profiled:

Piramal Pharma Solutions
Jubilant Life Sciences
Divi's Laboratories
Syngene International
Aurobindo Pharma
Biocon Limited
Dr. Reddy's Laboratories

India CDMO Market Segmentation

By Service Type

Contract Development Services
Contract Manufacturing Services

By Product Type

Small Molecules
Biologics
Biosimilars
Vaccines

By Scale of Operation

Commercial Scale
Clinical Scale

By Therapeutic Area

Oncology
Cardiovascular Diseases
Infectious Diseases
Central Nervous System (CNS) Disorders

Product Code: PMRREP34955

1. Executive Summary

1.1. India CDMO Market Snapshot, 2024 - 2031
1.2. Market Opportunity Assessment, 2024 - 2031, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations

2. Market Overview

2.1. Market Scope and Definition
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
2.3. Macro-Economic Factors
- 2.3.1. Global Sectorial Outlook
- 2.3.2. Global GDP Growth Outlook
- 2.3.3. Global Healthcare Spending Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

3.1. Regulatory Landscape
3.2. Service Adoption Analysis
3.3. Value Chain Analysis
3.4. Key Deals and Mergers
3.5. PESTLE Analysis
3.6. Porter's Five Force Analysis

4. India CDMO Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

4.1. Key Highlights
- 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
- 4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Bn) Analysis and Forecast
- 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019 - 2023
- 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024 - 2031
4.3. India CDMO Market Outlook: Service Type
- 4.3.1. Introduction / Key Findings
- 4.3.2. Historical Market Size (US$ Bn) Analysis, By Service Type, 2019 - 2023
- 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Service Type, 2024 - 2031
  - 4.3.3.1. Contract Development Services
  - 4.3.3.2. Preclinical Development
  - 4.3.3.3. Clinical Development
  - 4.3.3.4. Analytical and Bioanalytical Services
  - 4.3.3.5. Contract Manufacturing Services
  - 4.3.3.6. Active Pharmaceutical Ingredients (APIs) Manufacturing
  - 4.3.3.7. Finished Dosage Forms (FDFs) Manufacturing
  - 4.3.3.8. Biologics Manufacturing
  - 4.3.3.9. Packaging
4.4. Market Attractiveness Analysis: Service Type
4.5. India CDMO Market Outlook: Product Type
- 4.5.1. Introduction / Key Findings
- 4.5.2. Historical Market Size (US$ Bn) Analysis, By Product Type, 2019 - 2023
- 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product Type, 2024 - 2031
  - 4.5.3.1. Small Molecules
  - 4.5.3.2. Biologics
  - 4.5.3.3. Biosimilars
  - 4.5.3.4. Vaccines
  - 4.5.3.5. Others
4.6. Market Attractiveness Analysis: Product Type
4.7. India CDMO Market Outlook: Scale of Operation
- 4.7.1. Introduction / Key Findings
- 4.7.2. Historical Market Size (US$ Bn) Analysis, By Scale of Operation, 2019 - 2023
- 4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Scale of Operation, 2024 - 2031
  - 4.7.3.1. Commercial Scale
  - 4.7.3.2. Clinical Scale
4.8. Market Attractiveness Analysis: Scale of Operation
4.9. India CDMO Market Outlook: Therapeutic Area
- 4.9.1. Introduction / Key Findings
- 4.9.2. Historical Market Size (US$ Bn) Analysis, By Therapeutic Area, 2019 - 2023
- 4.9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2024 - 2031
  - 4.9.3.1. Oncology
  - 4.9.3.2. Cardiovascular Diseases
  - 4.9.3.3. Infectious Diseases
  - 4.9.3.4. Central Nervous System (CNS) Disorders
  - 4.9.3.5. Others
4.10. Market Attractiveness Analysis: Therapeutic Area

5. Competition Landscape

5.1. Market Share Analysis, 2023
5.2. Market Structure
- 5.2.1. Competition Intensity Mapping By Market
- 5.2.2. Competition Dashboard
5.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 5.3.1. Piramal Pharma Solutions
  - 5.3.1.1. Overview
  - 5.3.1.2. Segments and Products
  - 5.3.1.3. Key Financials
  - 5.3.1.4. Market Developments
  - 5.3.1.5. Market Strategy
- 5.3.2. Syngene International
- 5.3.3. Dr. Reddy's Laboratories
- 5.3.4. Divi's Laboratories
- 5.3.5. Lupin Limited
- 5.3.6. Sun Pharmaceutical Industries Ltd.
- 5.3.7. Aurobindo Pharma
- 5.3.8. Jubilant Pharmova (Jubilant Biosys & Jubilant Generics)
- 5.3.9. Glenmark Pharmaceuticals
- 5.3.10. Capsule Pharma
- 5.3.11. Laurus Labs
- 5.3.12. Strides Pharma Science
- 5.3.13. Aurigene Pharmaceutical

6. Appendix

6.1. Research Methodology
6.2. Research Assumptions
6.3. Acronyms and Abbreviations